Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Contrast-enhanced computed tomography (CT) of the neck-thorax-abdomen and pelvis,
including 3-phase examination of the liver, constitutes the basic imaging for primary …

Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with
neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …

Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine
has earned a major role in gastroenteropancreatic neuroendocrine tumors (GEP NETs) …

Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk
stratification and optimal choice of therapy. Currently, grading is based on histologically …